Previous Close | 7.28 |
Open | 7.32 |
Bid | 6.29 x 900 |
Ask | 12.00 x 900 |
Day's Range | 7.06 - 7.31 |
52 Week Range | 5.40 - 12.99 |
Volume | |
Avg. Volume | 128,208 |
Market Cap | 193.002M |
Beta (5Y Monthly) | 0.90 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.78 |
Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.38 |
Subscribe to Yahoo Finance Plus to view Fair Value for HROW
NASHVILLE, Tenn., June 24, 2022--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%. Harrow also announced that IOPIDINE 1% and MAXITROL are now commercially available; Harrow intends to commercialize MOXEZA 0.5% at a later date. Harrow purchased these medi
Source: iQoncept / Shutterstock.com Given the way the market’s acting today, now may not seem like the best time to pursue “moonshot” plays. Rising interest rates keep putting pressure on formerly high-flying growth stocks. Meme stocks are struggling to hold onto what’s left of their “to the moon” gains. Yet for investors, there’s an area that may provide such high-risk, high-potential opportunities: micro-cap stocks. Micro-caps, or stocks with market capitalizations under $300 million, are an u
Every investor in Harrow Health, Inc. ( NASDAQ:HROW ) should be aware of the most powerful shareholder groups...